Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Clinical trial NCT00837265 · COMPLETED

Trial details

NCT number: NCT00837265
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Chemotherapy-induced Neutropenia

Start date: 2008-08-21
Primary completion: 2009-06-26
Enrollment: 334

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.